News

Biotech investors like it when one of their companies reports gains in a developmental program, and that was the dynamic behind Tuesday's rise in the share price of Aclaris Therapeutics (NASDAQ:

Shares of Surmodics (NASDAQ: SRDX) were up 16% early Tuesday afternoon as the healthcare company, which provides chemicals for in vitro diagnostic immunoassay tests and makes coatings for

Biotech growth stocks are inherently risky due to the plethora of competitive, financial, clinical, and regulatory hurdles unique to the industry. Despite these various risk factors, however, most

A Qatari billionaire has reportedly won the auction for English Premier League club Manchester United (NYSE: MANU). The club's common shares are soaring as a result, up 10% on Tuesday morning.

CRISPR Therapeutics (NASDAQ: CRSP) and partner Vertex Pharmaceuticals just took another step closer to launching a potential game-changing product. At the same time, the U.S. Food and Drug

CRISPR Therapeutics (NASDAQ: CRSP) and partner Vertex Pharmaceuticals just took another step closer to launching a potential game-changing product. At the same time, the U.S. Food and Drug

CRISPR Therapeutics (NASDAQ: CRSP) and partner Vertex Pharmaceuticals just took another step closer to launching a potential game-changing product. At the same time, the U.S. Food and Drug

Shares of Omeros (NASDAQ: OMER) were down 12.9% early Monday afternoon after the clinical-stage biopharmaceutical company released a presentation it made regarding a therapy to treat a rare blood

The stock market has the potential to make just about anybody with enough patience and discipline a millionaire. This is because it has historically delivered 10% annual total returns over the long

These days, investors can find plenty of reasons to feel nervous about buying stocks. Surging inflation, soaring interest rates, and geopolitical tensions are all legitimate concerns for most

Pharmaceutical companies Novo Nordisk (NYSE: NVO) and AbbVie (NYSE: ABBV) seem to be headed in separate directions.

Denmark-based Novo Nordisk, thanks to growing sales of diabetes drug Ozempic and

Sell in May and go away? The old adage hasn't proven to be great advice in 2023. The stock market has risen so far in June and could go even higher.

Three Motley Fool contributors think some stocks

Shares of AngioDynamics (NASDAQ: ANGO) were up more than 8% Friday afternoon after rising as much as 9.1% on the news the medical technology company had sold some of its assets for $100 million. The

Biotech stocks have taken investors on an unpredictable ride so far in 2023. One of the most popular biotech exchange-traded funds (ETFs), the iShares Biotechnology ETF, which focuses mostly on

Biotech stocks have taken investors on an unpredictable ride so far in 2023. One of the most popular biotech exchange-traded funds (ETFs), the iShares Biotechnology ETF, which focuses mostly on

Biotech stocks have taken investors on an unpredictable ride so far in 2023. One of the most popular biotech exchange-traded funds (ETFs), the iShares Biotechnology ETF, which focuses mostly on

Biotech company Novavax (NASDAQ: NVAX) has fallen from grace over the past year, with the vaccine maker's shares dropping by 84% over the trailing-12-month period. But Wall Street hasn't given up on

Shares of MicroVision (NASDAQ: MVIS) are soaring again this week. Heading into today's trading session, the machine-vision specialist's share price had risen 46.6% from last Friday's market close

When patent protection expires on pharma companies' biggest sellers, it can be devastating for their finances. Due to the highly competitive nature of the pharmaceutical industry, it is no easy task

When patent protection expires on pharma companies' biggest sellers, it can be devastating for their finances. Due to the highly competitive nature of the pharmaceutical industry, it is no easy task

When patent protection expires on pharma companies' biggest sellers, it can be devastating for their finances. Due to the highly competitive nature of the pharmaceutical industry, it is no easy task